Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment

Optimising the management of patients with multiple myeloma in Spain: A measurement of the social... AbbreviationsAEALAsociación Española de Afectados de Linfoma, Mieloma y Leucemia (Spanish Association of People Affected by Lymphoma, Myeloma and Leukaemia)CEMMPComunidad Española de Pacientes con Mieloma Múltiple (Spanish Community of Multiple Myeloma Patients)CHEERSConsolidated Health Economic Evaluation Reporting StandardsCRABCalcium level, renal dysfunction, anaemia and destructive bone lesionsDDiagnosisEDHTEmergency Department, Hospitalisation and TransplantF/UFollow‐upFACT‐MMFunctional Assessment of Cancer for Therapy‐Multiple MyelomaGEPACGrupo Español de Pacientes con Cáncer (Spanish Group of Cancer Patients)MMillionMMMultiple myelomaMWTMultidisciplinary Working TeamSSupportSEEOSociedad Española de Enfermería Oncológica (Spanish Society of Oncology Nursing)SEFH‐GEDEFOSociedad Española de Farmacia Hospitalaria‐Grupo Español para el Desarrollo de la Farmacia Oncológica (Spanish Society of Hospital Pharmacy‐Spanish Group for the Development of the Oncology Pharmacy)SEHHSociedad Española de Hematología y Hemoterapia (Spanish Society of Haematology and Hemotherapy)SEMERGENSociedad Española de Médicos de Atención Primaria (Spanish Society of Primary Care Physicians)SNHSSpanish National Health SystemSROISocial Return on InvestmentINTRODUCTIONMultiple myeloma (MM) is a cancer of the plasma cells of the bone marrow (International Myeloma Foundation, 2019) that accounts for 1% of all cancers and around 10% of all haematological malignancies (Moreau et al., 2017). In Spain, the annual incidence rate is 7.0/100,000 inhabitants, and the annual mortality rate is 4.6/100,000 inhabitants, which resulted in 3,261 new cases and 2,114 deaths related to MM in 2018 (Ferlay et al., 2018). Progression of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment

Download PDF
9 pages

Loading next page...
 
/lp/wiley/optimising-the-management-of-patients-with-multiple-myeloma-in-spain-a-RQBNJz1Evo

References (43)

Publisher
Wiley
Copyright
© 2022 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.13706
Publisher site
See Article on Publisher Site

Abstract

AbbreviationsAEALAsociación Española de Afectados de Linfoma, Mieloma y Leucemia (Spanish Association of People Affected by Lymphoma, Myeloma and Leukaemia)CEMMPComunidad Española de Pacientes con Mieloma Múltiple (Spanish Community of Multiple Myeloma Patients)CHEERSConsolidated Health Economic Evaluation Reporting StandardsCRABCalcium level, renal dysfunction, anaemia and destructive bone lesionsDDiagnosisEDHTEmergency Department, Hospitalisation and TransplantF/UFollow‐upFACT‐MMFunctional Assessment of Cancer for Therapy‐Multiple MyelomaGEPACGrupo Español de Pacientes con Cáncer (Spanish Group of Cancer Patients)MMillionMMMultiple myelomaMWTMultidisciplinary Working TeamSSupportSEEOSociedad Española de Enfermería Oncológica (Spanish Society of Oncology Nursing)SEFH‐GEDEFOSociedad Española de Farmacia Hospitalaria‐Grupo Español para el Desarrollo de la Farmacia Oncológica (Spanish Society of Hospital Pharmacy‐Spanish Group for the Development of the Oncology Pharmacy)SEHHSociedad Española de Hematología y Hemoterapia (Spanish Society of Haematology and Hemotherapy)SEMERGENSociedad Española de Médicos de Atención Primaria (Spanish Society of Primary Care Physicians)SNHSSpanish National Health SystemSROISocial Return on InvestmentINTRODUCTIONMultiple myeloma (MM) is a cancer of the plasma cells of the bone marrow (International Myeloma Foundation, 2019) that accounts for 1% of all cancers and around 10% of all haematological malignancies (Moreau et al., 2017). In Spain, the annual incidence rate is 7.0/100,000 inhabitants, and the annual mortality rate is 4.6/100,000 inhabitants, which resulted in 3,261 new cases and 2,114 deaths related to MM in 2018 (Ferlay et al., 2018). Progression of

Journal

European Journal of Cancer Care – Wiley

Published: Nov 1, 2022

Keywords: cost–benefit analysis; disease management; haematological malignancies; multiple myeloma; social return on investment (SROI); Spanish national health system

There are no references for this article.